Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isunakinra and Pembrolizumab in Advanced Colorectal Cancer
NCT06634875Phase 2Recruiting
- Sponsor
- Buzzard Pharmaceuticals AB
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of isunakinra in colorectal cancer (CRC), sponsored by Buzzard Pharmaceuticals AB. Primary endpoints: Safety at 6 months and Progression-Free Survival at 6 months. Started Jan 2025; status: recruiting.
02
Drugs
isunakinra
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06634875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634875.